论文部分内容阅读
目的探讨恶性黑色素瘤(MM)根治术后自体树突状细胞(DC)疫苗辅助治疗的临床疗效。方法 42例Ⅱ、Ⅲ期肢体MM术后患者分为两组,30例患者接受白细胞介素2(IL-2)/干扰素-α2b(IFN-α2b)常规免疫治疗(常规组),12例患者常规治疗同时联合DC疫苗(疫苗组)。观察DC疫苗的临床安全性和对患者免疫功能的影响。结果与常规组比较,疫苗组治疗后外周血CD3+、CD3+CD4+、CD4+/CD8+比值、自然杀伤(NK)细胞比率明显升高(P<0.05),治疗中无严重不良反应发生。随访结果显示,DC疫苗治疗能够显著延长根治手术后MM患者的无复发生存期。结论联合DC疫苗的免疫治疗能够提高MM根治术后患者的免疫功能,降低其复发转移,可作为MM患者安全有效的辅助治疗手段。
Objective To investigate the clinical efficacy of adjuvant therapy with autologous dendritic cells (DC) vaccine in the treatment of malignant melanoma (MM). Methods Forty-two patients with stage II and III limb MM were divided into two groups. Thirty patients received conventional immunotherapy (conventional group) with IL-2 / IFN-α2b (routine group), and 12 patients Patients were treated routinely with DC vaccine (vaccine group). To observe the clinical safety of DC vaccines and immune function of patients. Results Compared with the conventional group, the ratio of CD3 +, CD3 +, CD4 + / CD8 + and NK cells in the vaccine group were significantly increased (P <0.05) after treatment. There was no serious adverse reaction in the treatment. Follow-up results showed that DC vaccine treatment can significantly prolong the recurrence-free survival of patients with MM after radical operation. Conclusions The immunotherapy combined with DC vaccine can improve the immune function and reduce the recurrence and metastasis of MM patients after radical mastectomy, which can be used as a safe and effective adjuvant therapy for MM patients.